Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV+HMPV Vaccine in Adults 60 Years and Older
NCT07734649Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of SP0256 in respiratory syncytial virus infection (RSV), human metapneumovirus infection (HMPV), sponsored by Sanofi. Started Jul 2026; status: recruiting.
02
Drugs
SP0256
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT07734649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734649.